Retour sur lavenir.net
   NYXOAH 1.372 € (-0,87 %)     AGEAS 72.300 € (+2,12 %)     AB INBEV 73.060 € (+2,21 %)     SOFINA 233.800 € (+2,01 %)     ACKERMANS V.HAAREN 270.000 € (+0,52 %)     UCB 243.600 € (-0,12 %)     AEDIFICA 70.650 € (+1,07 %)     BARCO 7.990 € (+2,50 %)     D'IETEREN GROUP 174.300 € (+1,10 %)     MONTEA 69.100 € (+1,77 %)     GBL 78.300 € (+1,42 %)     WDP 22.700 € (+2,71 %)     ARGENX SE 761.000 € (+0,11 %)     SOLVAY 26.360 € (+1,46 %)     HOME INVEST BE. 19.780 € (+1,64 %)     BPOST 1.574 € (+0,25 %)     AZELIS GROUP 10.680 € (+1,62 %)     TESSENDERLO 21.000 € (+2,44 %)     GIMV 44.900 € (+0,79 %)     KBC 123.000 € (+0,53 %)     SIPEF 95.600 € (+3,46 %)     CENERGY 22.060 € (+3,76 %)     IBA 16.720 € (-0,12 %)     KBC ANCORA 87.400 € (+0,23 %)     EVS 26.850 € (-0,19 %)     SYENSQO 70.500 € (+1,73 %)     ELIA GROUP 140.200 € (+1,89 %)     RECTICEL 12.120 € (+0,83 %)     MIKO 67.000 € (+1,52 %)     MELEXIS 73.500 € (+2,08 %)     UMICORE 20.260 € (+1,50 %)     PROXIMUS 6.095 € (+0,58 %)     DECEUNINCK 2.185 € (+0,46 %)     VASTNED 29.250 € (-0,17 %)     EXMAR 11.400 € (+0,44 %)     DEME GROUP 170.200 € (+0,83 %)     TINC 11.400 € (+2,33 %)     LOTUS BAKERIES 10 840.000 € (+0,37 %)     FAGRON 23.700 € (-0,63 %)     TITAN S.A. 50.900 € (+4,30 %)     COLRUYT 38.160 € (+0,58 %)     SOLVAC NOM(RETAIL) 77.000 € (+2,67 %)     SHURGARD 25.400 € (+0,79 %)     CMB.TECH 13.720 € (+0,73 %)     BELYSSE GROUP 0.480 € (0,00 %)     BIOTALYS 2.980 € (0,00 %)     RETAIL ESTATES 69.100 € (+2,22 %)     TUBIZE-FIN 209.400 € (+0,19 %)     VGP 82.800 € (+2,10 %)     ORANGE BELGIUM 21.700 € (0,00 %)     FLUXYS BELGIUM D 19.900 € (+2,05 %)     IMMOBEL 21.700 € (-1,36 %)     CARE PROPERTY INV. 12.840 € (+1,58 %)     BEKAERT 41.350 € (+0,24 %)     ONWARD MEDICAL 2.490 € (+0,20 %)     AGFA-GEVAERT 0.390 € (-1,14 %)     QRF 10.250 € (+0,49 %)     CIE BOIS SAUVAGE 307.000 € (+1,99 %)     KINEPOLIS GROUP 38.700 € (+0,13 %)     HYLORIS 4.620 € (+0,43 %)  
   FDJ UNITED 22.800 € (-0,09 %)     VIRIDIEN 82.600 € (+1,10 %)     LOUIS HACHETTE 1.715 € (+1,30 %)     SCHNEIDER ELECTRIC 269.950 € (+0,43 %)     LAGARDERE SA 18.100 € (-0,33 %)     ASML HOLDING 1 565.400 € (-1,76 %)     GALP ENERGIA-NOM 20.040 € (+0,63 %)     VEOLIA ENVIRON. 37.160 € (+1,59 %)     ADYEN 821.500 € (+0,11 %)     AIR FRANCE -KLM 11.810 € (-1,79 %)     SOITEC 97.120 € (+1,72 %)     ASM INTERNATIONAL 886.000 € (-1,84 %)     TOTALENERGIES 73.860 € (+1,44 %)     AXA 45.360 € (+1,27 %)     HEIJMANS KON 99.200 € (+0,97 %)     CAPITAL B 0.501 € (-1,18 %)     KLEPIERRE 38.100 € (+0,26 %)     TEIXEIRA DUARTE 0.501 € (+3,51 %)     GENFIT 13.720 € (-2,42 %)     STIF 53.200 € (+0,85 %)     KERING 250.350 € (-0,24 %)     SENSORION 0.259 € (-0,58 %)     ENGIE 27.590 € (+2,07 %)     AEGON 8.090 € (+0,87 %)     QUADIENT 12.980 € (+1,72 %)     RANDSTAD NV 35.580 € (+11,68 %)     ASR NEDERLAND 70.700 € (+1,52 %)     BRUNEL INTERNAT 7.450 € (+5,08 %)     LEGRAND 137.300 € (+0,04 %)     ACCOR 46.410 € (+0,11 %)     EUTELSAT COMMUNIC. 2.174 € (+3,72 %)     PHILIPS KON 23.390 € (+0,21 %)     EXOSENS 61.050 € (+1,08 %)     VALEO 13.075 € (+0,31 %)     VERALLIA 19.440 € (+1,78 %)     BE SEMICONDUCTOR 242.200 € (+1,13 %)     MEXEDIA 3.010 € (+0,33 %)     NN GROUP 79.940 € (+0,93 %)     TECHNIP ENERGIES 34.220 € (+0,71 %)     EXOR NV 69.000 € (+1,55 %)     LVMH 478.050 € (-0,10 %)     CREDIT AGRICOLE 18.205 € (+0,55 %)     BNP PARIBAS ACT.A 106.480 € (+1,26 %)     ETHERO 0.485 € (+0,94 %)     COFACE 16.300 € (+1,24 %)     IMCD 89.340 € (+1,57 %)     UNILEVER 53.680 € (+0,45 %)     SHELL PLC 38.600 € (+1,02 %)     KPN KON 4.218 € (-0,68 %)     STMICROELECTRONICS 57.640 € (+0,68 %)     PERNOD RICARD 63.720 € (+1,79 %)     SBM OFFSHORE 32.720 € (+1,18 %)     TELEPERFORMANCE 55.880 € (+4,80 %)     CSG 15.736 € (+6,97 %)     SAFRAN 325.300 € (+0,74 %)     SANOFI 77.500 € (+0,98 %)     ORANGE 16.265 € (+0,49 %)     ABN AMRO BANK N.V. 38.460 € (+0,71 %)     APERAM 46.940 € (+0,04 %)     AIRBUS 206.400 € (+6,06 %)  
News Réglementées
14/07/2026 17:30

NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

EQS-News: National Association for Biomedical Research / Key word(s): Miscellaneous/Miscellaneous
NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

14.07.2026 / 17:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


WASHINGTON, July 14, 2026 /PRNewswire/ -- On July 14, 2026, the U.S. Fish and Wildlife Service ("USFWS") for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals ("PETA") and other activist groups to list long-tailed macaque ("LTM") monkeys (Macaca fascicularis) under the U.S. Endangered Species Act ("ESA").

NABR-Logo-1.jpg?id=OA2762918

The U.S. Fish and Wildlife Service determined that PETA's petition1 to list LTM monkeys under the ESA does not present substantial scientific information warranting further review. This is the second time USFWS has rejected a petition from PETA to list this nonhuman primate species in the last three years2.

"The National Association for Biomedical Research commends USFWS for conducting a thorough, science-based review of the petition submitted by activist groups and for its determination that LTM monkeys do not warrant listing under the ESA," said Matthew R. Bailey, president, National Association for Biomedical Research (NABR).

"It is clear from the record that activist groups like PETA have attempted to weaponize the ESA and other environmental processes to block or hinder medical research in the United States and around the world. Doing so not only jeopardizes human health and safety, but it undermines the value of these environmental processes when they are used as tools to further political agendas," added Mr. Bailey.

"NABR will continue to engage in these processes to protect medical research in the U.S. and around the world to ensure decisions regarding species protection are based on the best available scientific and commercial data."

LTM monkeys are used extensively throughout the world in biomedical research given their close approximation to human beings. The importation and use of this nonhuman primate species in biomedical research is strictly regulated by international bodies and U.S. federal agencies.

Medical research using LTM monkeys has been crucial for advances in regenerative medicine3, immunology4, cancer5, vaccine development6, and pharmacology7. The National Institutes of Health (NIH) recently published a review confirming the importance of LTM monkeys in conducting biomedical research8.

"Due to their physiological and biological similarities with humans, LTM monkeys are a crucial resource for pre-clinical biomedical research. They contribute to the development of therapies before the human clinical trial stage of development," said Mr. Bailey. "LTM monkeys have been instrumental in the development, and in safety and efficacy assessment, of many of today's medicines and treatments. They continue to be invaluable for biomedical advancements."

About the National Association for Biomedical Research
Founded in 1979, the National Association for Biomedical Research (NABR) is the only 501(c)(6) nonprofit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 280 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at www.nabr.org.


1 https://www.peta.org/media/news-releases/peta-primate-experts-file-legal-petitions-to-new-administration-to-protect-monkeys-not-profits/
2 https://www.nabr.org/about-nabr/news/fish-wildlife-service-long-tailed-macaques-esa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848615/#:~:text=Non%2Dhuman%20primates%20play%20a,organs%20affected%20by%20degenerative%20diseases. regenerative medicine
4 https://www.nature.com/articles/s41577-018-0005-7. immunology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808758/#:~:text=Furthermore%2C%20NHP%20naturally%20develop%20cancers,and%20patients%20with%20human%20cancer. cancer therapies
6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402317/. vaccine development
7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886327/. pharmacology
8 https://orip.nih.gov/about-orip/research-highlights/nonhuman-primate-evaluation-and-analysis-final-report 

Eva Maciejewski
emaciejewski@nabr.org
(202) 967-8305

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/nabr-the-us-fish-and-wildlife-service-for-the-second-time-rejects-activists-petition-to-list-long-tailed-macaque-monkeys-under-the-endangered-species-act-302825307.html

rt.gif?NewsItemId=EN04190&Transmission_Id=202607141127PR_NEWS_EURO_ND__EN04190&DateId=20260714


14.07.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2365824  14.07.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière